Marie David, MD
General Practice · Merced, CANPI 1831202233
Payments from drug & device makers
Across 63 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$708
- Novo Nordisk$263
- Pfizer$117
- Idorsia Pharmaceuticals US Inc$63
- Lilly USA, LLC$56
- Otsuka America Pharmaceutical, Inc.$56
- plus $262 from 11 others
What the payments were for
- Food & beverage$1,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $708 |
| Novo Nordisk | 4 | $263 |
| Pfizer | 6 | $117 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Lilly USA, LLC | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Johnson & Johnson | 2 | $38 |
| AstraZeneca | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Amgen | 1 | $28 |
| Organon | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| GSK | 1 | $19 |
| Mannkind Corporation | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$103
How this compares
$1,524 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 11 | $17,175 |
| Losartan Potassium | 63 | $858 |
| Atorvastatin Calcium | 57 | $746 |
| Levothyroxine Sodium | 56 | $686 |
| Omeprazole | 32 | $647 |
| Lisinopril | 31 | $330 |
| Simvastatin | 27 | $284 |
| Gabapentin | 13 | $247 |
| Sertraline Hcl | 11 | $184 |
| Tamsulosin Hcl | 12 | $174 |
| Montelukast Sodium | 15 | $167 |
| Metoprolol Tartrate | 15 | $154 |
| Metoprolol Succinate | 23 | $139 |
| Metformin Hcl | 16 | $109 |
| Hydrochlorothiazide | 22 | $102 |
Paid to pharmacies, not to this prescriber.
Other general practice in Merced
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.